Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Cancer Cell(2025)10.1016/j.ccell.2025.02.008Source: DataRank Database

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia is a research paper published in Cancer Cell (2025). On theSindex it has a DataRank of 0.488. It has been cited 17 times, with 14 citing works in its 1-hop citation network.

N/A

0.488DataRank · unranked

Scored on demand from live citation data

Open Access17 citations · 14 citing works in its network

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 8.45)OA: hybridTopics (27)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 89%Citation Network 11%

Base Score Contribution

0.434

From this paper's citation signal

Citation Network Contribution

0.0541

From 7 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 14 citers.

Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy
Nature Cancer20256 citations76 referencesContributes 0.026
Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospects
Clinical Cancer Bulletin20253 citations131 referencesContributes 0.011
Next-generation in vivo CAR-T expansion strategies: Unlocking durable anti-tumor responses in solid tumors
Critical Reviews in Oncology/Hematology20261 citations86 referencesContributes 0.008
Advances in chimeric antigen receptor-T therapies to target tumor resistance in B-cell malignancies
Current Opinion in Hematology20251 citations90 referencesContributes 0.008
The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer20251 citations130 referencesContributes 0.005

Authors (9)

Amanda J Novak ORCID,Etienne Danis ORCID,Samantha M. McClellan,Lillie Leach,Michael Yarnell ORCID

Live enrichment

PubMed:40068599 OpenAlex:https://openalex.org/W4408290605

U.S. Department of Defense

Grant: TTSA CA180683P1

Leukemia and Lymphoma Society

Grant: K12CA086913-18

Leukemia and Lymphoma Society

Grant: R01CA269269

Leukemia and Lymphoma Society

Grant: R01CA260909

Leukemia and Lymphoma Society

Grant: SCOR 7033-24

NIH

Grant: S10-OD025267

American Society of Hematology

Grant: T2024-025

Cancer Center, University of Colorado

Grant: SCR021980

NIH NCI

Grant: /NCI 1U01CA232486

NIH NCI

Grant: 1U01CA243072

FWCI

8.45

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ccell.2025.02.008

publisherhttps://doi.org/10.1016/j.ccell.2025.02.008

publisherhttps://api.elsevier.com/content/article/PII:S1535610825000601?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610825000601?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40068599

Fields of Study

CAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses

MeSH Terms

Receptors, Chimeric AntigenAnimalsHumansLymphocyte ActivationMembrane ProteinsPhosphorylationT-LymphocytesSignal TransductionImmunotherapy, AdoptiveXenograft Model Antitumor AssaysCell Line, TumorAdaptor Proteins, Signal TransducingCell ProliferationMiceSialic Acid Binding Ig-like Lectin 2Precursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

Persistence (discontinuity)Lymphoblastic LeukemiaAntigenImmunologyLeukemiaCancer researchBiologyMedicine

Sustainable Development Goals

SDG 0: Life in Land